Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia

References

• Locke III GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–561. Locke III GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–56
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004;19:643–542. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004;19:643–54
   PubMed Web of Science ®Google Scholar
• Drossman DA, Corazziari E, Delvaux M, et al. Rome III. The Functional Gastrointestinal Disorders, 3rd ed. McLean, VA: Degnon Associates; 20063. Drossman DA, Corazziari E, Delvaux M, et al. Rome III. The Functional Gastrointestinal Disorders, 3rd ed. McLean, VA: Degnon Associates; 2006
   Google Scholar
• Drossman DA, Corazziari E, Talley NJ, et al. Rome II: The Functional Gastrointestinal Disorders, 2nd ed. McLean, VA: Degnon Associates; 20004. Drossman DA, Corazziari E, Talley NJ, et al. Rome II: The Functional Gastrointestinal Disorders, 2nd ed. McLean, VA: Degnon Associates; 2000
   Google Scholar
• Rodriguez-Stanley S, Wolff M, Proskin HM, Miner PB Jr. Gastrointestinal symptom profile in patients with functional heartburn. Gastroenterology 2004;126 Suppl 2:A3805. Rodriguez-Stanley S, Wolff M, Proskin HM, Miner PB Jr. Gastrointestinal symptom profile in patients with functional heartburn. Gastroenterology 2004;126 Suppl 2:A380
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466–796. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466–79
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329–377. Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329–37
   PubMed Web of Science ®Google Scholar
• Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547–558. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547–55
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765–739. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765–73
   PubMed Web of Science ®Google Scholar
• Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974–910. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974–9
   PubMed Web of Science ®Google Scholar
• Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002;51:885–9211. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002;51:885–92
   PubMed Web of Science ®Google Scholar
• Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004;2:796–80512. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004;2:796–805
   PubMed Web of Science ®Google Scholar
• Kamm MA, Müller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005;100:362–7213. Kamm MA, Müller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005;100:362–72
   PubMed Web of Science ®Google Scholar
• Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–6614. Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–66
   PubMed Web of Science ®Google Scholar
• Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877–8815. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877–88
   PubMed Web of Science ®Google Scholar
• Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 2005;54:1707–1316. Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 2005;54:1707–13
   PubMed Web of Science ®Google Scholar
• Degen L, Petrig C, Studer D, et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005;17:821–617. Degen L, Petrig C, Studer D, et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005;17:821–6
   PubMed Web of Science ®Google Scholar
• Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745–5118. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745–51
   PubMed Web of Science ®Google Scholar
• Tougas G, Cheng Y, Luo D, et al. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003;124 Suppl 2:A5419. Tougas G, Cheng Y, Luo D, et al. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003;124 Suppl 2:A54
   Web of Science ®Google Scholar
• Tack J, Vos R, Tougas G, et al. Effect of tegaserod, a 5-HT4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastoenterology 2005;128 Suppl 2:A9420. Tack J, Vos R, Tougas G, et al. Effect of tegaserod, a 5-HT4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastoenterology 2005;128 Suppl 2:A94
   Web of Science ®Google Scholar
• Thumshirn M, Fruehauf H, Stutz B, et al. Effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia and healthy controls. Gastroenterology 2005;128 Suppl 2:A46921. Thumshirn M, Fruehauf H, Stutz B, et al. Effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia and healthy controls. Gastroenterology 2005;128 Suppl 2:A469
   Web of Science ®Google Scholar
• Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577–8522. Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577–85
   PubMed Web of Science ®Google Scholar
• Tack J, Vos R, Janssens J, et al. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003;18:1031–723. Tack J, Vos R, Janssens J, et al. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003;18:1031–7
   PubMed Web of Science ®Google Scholar
• Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006;4:442–5024. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006;4:442–50
   PubMed Web of Science ®Google Scholar
• Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley; 198625. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley; 1986
   Google Scholar
• Higgins JJ. Introduction to Modern Nonparametric Statistics. Pacific Grove, CA: Brooks/Cole-Thomson Learning; 200426. Higgins JJ. Introduction to Modern Nonparametric Statistics. Pacific Grove, CA: Brooks/Cole-Thomson Learning; 2004
   Google Scholar
• Julious SA. Sample sizes for clinical trials with normal data. Stat Med 2004;23:1921–8627. Julious SA. Sample sizes for clinical trials with normal data. Stat Med 2004;23:1921–86
   PubMed Web of Science ®Google Scholar
• Troncon LE, Thompson DG, Ahluwalia NK, et al. Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy. Gut 1995;37:17–2228. Troncon LE, Thompson DG, Ahluwalia NK, et al. Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy. Gut 1995;37:17–22
   PubMed Web of Science ®Google Scholar
• Zelnorm/Zelmac® basic prescribing information. Novartis. March 25, 2008. Novartis tracking number 2008-PSB/GLC-0124-s29. Zelnorm/Zelmac® basic prescribing information. Novartis. March 25, 2008. Novartis tracking number 2008-PSB/GLC-0124-s
   Google Scholar
• Bouras EP, Gado-Aros S, Camilleri M, et al. SPECT imaging of the stomach: comparison with Barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 2002;51:781–630. Bouras EP, Gado-Aros S, Camilleri M, et al. SPECT imaging of the stomach: comparison with Barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 2002;51:781–6
   PubMed Web of Science ®Google Scholar